Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes
Animal Models and Experimental Medicine · 2025
DOI: 10.1002/ame2.12505 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2025. Verfasst von Wang Nenhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Center for Disease Prevention and Control, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Fluoroquinolones, Rifampin, Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Research and Cultivation Spectial Project of Beijing Center for Disease Prevention and Control.
Abstract (Originalsprache)
Background
China is a high‐burden country for multidrug‐resistant tuberculosis/rifampin‐resistant tuberculosis (MDR/RR‐TB). Fluoroquinolones (FQs) are key drugs for the treatment of patients with MDR/RR‐TB. However, research on the resistance of FQs in Beijing is limited.
Methods
We collected clinical isolates from all patients with pulmonary TB in Beijing from January 2016 to December 2021, conducted drug‐sensitivity tests and sequencing for levofloxacin (LFX) and moxifloxacin (MFX), and collected the treatment plans and outcomes of the patients.
Results
A total of 8512 clinical isolates were collected from patients with pulmonary TB, and 261 RR‐TB strains were screened. The proportions of drug‐sensitive and drug‐resistant strains significantly differed by age group and treatment history. The rates of LFX and MFX resistance were 27.6% (72/261) and 36.4% (95/261), respectively. The detection rates of MDR‐TB and pre‐extensively drug‐resistant TB (pre‐XDR‐TB) were 73.2% (191/261) and 36.4% (95/261), respectively, and the trends were significant ( χ 2 trend = 9.995, p = 0.002; χ 2 trend = 12.744, p = 0.026). Among the 261 RR‐TB strains, 14.9% (24/261) were sensitive to LFX but resistant to MFX. Among the four patients with LFX‐resistant TB who received LFX treatment failed in three patients(Fisher's exact test, p = 0.009). The common mutation sites were 94 and 90 in gyrA. A novel mutation Ala90Ser was discovered.
Conclusions
FQs resistance trends in RR‐TB patients in Beijing are striking. Strains showed incomplete cross‐resistance to LFX and MFX. Testing for FQs resistance and developing a reasonable treatment plan are recommended. Attention should be given to the changing trends in MDR‐TB and pre‐XDR‐TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Center for Disease Prevention and Control, Beijing, People's Republic of China.
- Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
ORCID-Profile: Dai Xiaowei
Förderung
- The Research and Cultivation Spectial Project of Beijing Center for Disease Prevention and Control
Zitieren
APA
Nenhan, W., Lili, T., Yanfeng, Z., Shuangshuang, C., LiYing, T., Qiao, L., Chuanyou, L., & Xiaowei, D. (2025). Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12505
Vancouver
Nenhan W, Lili T, Yanfeng Z, Shuangshuang C, LiYing T, Qiao L, et al. Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes. Animal Models and Experimental Medicine. 2025. doi:10.1002/ame2.12505
BibTeX
@article{Nenhan2025,
author = {Nenhan, Wang and Lili, Tian and Yanfeng, Zhao and Shuangshuang, Chen and LiYing, Tao and Qiao, Li and Chuanyou, Li and Xiaowei, Dai},
title = {Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes},
journal = {Animal Models and Experimental Medicine},
year = {2025},
doi = {10.1002/ame2.12505}
}
EUVIMED